Literature DB >> 12888070

Toxoplasmosis transmitted to a newborn from the mother infected 20 years earlier.

Claudio Silveira1, Rosane Ferreira, Cristina Muccioli, Robert Nussenblatt, Rubens Belfort.   

Abstract

PURPOSE: To present a case of congenital toxoplasmosis in a newborn whose mother had a 20-year history of a chorioretinal macular scar and positive serology for toxoplasmosis. DESIGN/
METHODS: Case report. SETTING/
RESULTS: A 38-year-old woman who had been treated for ocular toxoplasmosis 20 years earlier delivered a newborn who presented with a focal necrotizing retinochoroiditis characteristic of toxoplasmosis, as well as positive immunoglobulin (Ig) G and M serology for toxoplasmosis. The workup was negative for other entities.
CONCLUSION: This case suggests that women with old retinal scars due to toxoplasmosis and long-standing IgG antibodies to toxoplasmosis are also at risk of transmitting this disease to the fetus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12888070     DOI: 10.1016/s0002-9394(03)00191-0

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  16 in total

1.  Frequency of Toxoplasma gondii in the retina in eye banks in Brazil.

Authors:  Deise F Costa; Heloisa Nascimento; Aline Sutili; Fernando A J Nobrega; Flavio Fowler; Mario Junqueira Nobrega; Cristina Garrido; Janaina de Oliveira Dias; Consuelo B D Adán; Luiz Vicente Rizzo; Claudio Silveira; Rubens Belfort; Alessandra G Commodaro
Journal:  Parasitol Res       Date:  2017-05-15       Impact factor: 2.289

2.  Activation of toxoplasma retinochoroiditis during pregnancy and evaluation of ocular findings in newborns.

Authors:  Fatih Mehmet Türkcü; Alparslan Şahin; Harun Yüksel; Yasin Çınar; Kürşat Cingü; Suat Altındağ; Özcan Deveci; Zeynep Özkurt; İhsan Çaça
Journal:  Int Ophthalmol       Date:  2016-08-01       Impact factor: 2.031

3.  HLA-DQA1/B1 alleles as putative susceptibility markers in congenital toxoplasmosis.

Authors:  Paulo Tadashi Shimokawa; Lília Spaleta Targa; Lidia Yamamoto; Jonatas Cristian Rodrigues; Kelly Aparecida Kanunfre; Thelma Suely Okay
Journal:  Virulence       Date:  2016-02-08       Impact factor: 5.882

Review 4.  Ocular toxoplasmosis II: clinical features, pathology and management.

Authors:  Nicholas J Butler; João M Furtado; Kevin L Winthrop; Justine R Smith
Journal:  Clin Exp Ophthalmol       Date:  2012-09-17       Impact factor: 4.207

5.  Ocular toxoplasmosis: lessons from Brazil.

Authors:  Michael E Grigg; Jitender P Dubey; Robert B Nussenblatt
Journal:  Am J Ophthalmol       Date:  2015-06       Impact factor: 5.258

Review 6.  Toxoplasma gondii in South America: a differentiated pattern of spread, population structure and clinical manifestations.

Authors:  Gabriella de Lima Bessa; Ricardo Wagner de Almeida Vitor; Erica Dos Santos Martins-Duarte
Journal:  Parasitol Res       Date:  2021-08-14       Impact factor: 2.289

7.  Toxoplasma gondii antibody profile in HIV-infected pregnant women and the risk of congenital toxoplasmosis.

Authors:  E G Lago; G S Conrado; C S Piccoli; R L Carvalho; A L Bender
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-10-15       Impact factor: 3.267

8.  Interferon-γ and IL-10 Release Assay for Patients with Ocular Toxoplasmosis.

Authors:  Marcelo Rudzinski; Lais Pardini; Mariana Bernstein; Gastón Moré; Marina Khoury; Silvana Carolina Duarte; Carina Argüelles; Silvia Reina; José Raúl Oubiña
Journal:  Am J Trop Med Hyg       Date:  2020-09-03       Impact factor: 3.707

9.  Toxoplasma retinochoroiditis in pregnancy: Using current evidence to inform management.

Authors:  Remin Nath; Edward Guy; Anne Morrison; Simon P Kelly
Journal:  Clin Ophthalmol       Date:  2009-12-29

10.  Serological Responses to Toxoplasma gondii and Matrix Antigen 1 Predict the Risk of Subsequent Toxoplasmic Encephalitis in People Living With Human Immunodeficiency Virus (HIV).

Authors:  Jianchun Xiao; Fiona Bhondoekhan; Eric C Seaberg; Otto Yang; Valentina Stosor; Joseph B Margolick; Robert H Yolken; Raphael P Viscidi
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.